Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

April 30, 2009

Conditions
Cancer
Interventions
DRUG

MBP-426

Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.

Trial Locations (2)

78245

Institute for Drug Development, San Antonio

77030-4009

M.D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

Mebiopharm Co., Ltd

INDUSTRY

NCT00355888 - Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter